The European Association for the Study of the Liver (EASL) renews its Publishing Partnership with Elsevier
Amsterdam, 30 June 2009 – Elsevier, the leading publisher of scientific, technical and medical information, is pleased to announce its renewed publishing partnership with The European Association for the Study of the Liver (EASL), the leading European association in the field of liver research. The agreement calls for Elsevier to publish the society’s flagship journal, the Journal of Hepatology, for the next five years.
EASL is a society with over 1500 members. The society has given rise to a significant number of international clinical trials and research collaborations in liver disease for the benefit of patients all over the world. EASL’s flagship journal – the Journal of Hepatology - requires high standard quality contents and is highly perceived in its field. The journal publishes original papers, reviews, case reports and letters to the editor concerned with clinical and basic research in the field of hepatology.
“I am thankful to work with a professional learned society and also very grateful for its support and input over the last years. I look forward to working with the newly appointed Editor-in-Chief, Professor Didier Samuel and his editorial team. The management and cure of, for instance, infectious liver diseases like Hepatitis B and C as well as the advanced search for the basic mechanisms of liver failure are major and global challenges of the 21st century. Elsevier is confident to make the Journal of Hepatology a continuing and growing success for authors, readers and for EASL” commented Koos Admiraal MD, Publisher for Elsevier (https://www.elsevier.com/wps/find/homepage.cws_home).
# # #
About the European Association for the Study of the Liver (EASL)
In the forty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost Hepatology experts as members, and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
EASL’s work continues throughout the year with a vast portfolio of activities and initiatives. These include:
- The International Liver Congress™ which lasts several days and attracts upwards of 7000 participants
- EASL meetings including Monothematic conferences, Post Graduate courses and other EASL endorsed meetings that take place throughout the year
- EASL Schools of Hepatology, a series of events covering different aspects in the field of Hepatology. Residential courses with a limited attendance (30 to 50 participants), intense interaction, time for personal discussion and exchanges with a distinguished faculty. A balanced blend of theoretical and practical lectures with clinical case-based discussions targeting young fellows enrolled in hepatology-oriented departments, or more experienced clinicians who want to be exposed to the newest trends in hepatology.
- The Journal of Hepatology, published monthly with a readership of over 40,000
- Presenting new initiatives for European liver policy change at EU level
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
+31 20 485 3747